Consensus Avalo Therapeutics, Inc.

Stocks

AVTX

US05338F3064

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 28/08/2026 BST			5-day change	1st Jan Change
19.59 ^USD	-2.29%		-1.21%	+7.87%

08-19	Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing	MT
08-06	Avalo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Avalo Therapeutics, Inc.

Evolution of the Target Price: Avalo Therapeutics, Inc.

Changes in Analyst Recommendations: Avalo Therapeutics, Inc.

bade51a1e0492.DHSfzQkH5OmBawFA1K81757dzL9Hr-pj6VfV2mu1YoI.YzqymUFMvqzMM3E0i8xMnf3vmMx07qlU0WaC7V7zUPR0GNCJOmyFoPJTcg~69a20f393bf09ff7d114fc44e78c2e5c

Analysts' recommendations: Avalo Therapeutics, Inc.

06-12	Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says	MT
06-12	BofA Initiates Avalo Therapeutics at Buy With $35 Price Target	MT
05-14	Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating	MT
05-14	Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating	MT
05-06	Wedbush Adjusts Price Target on Avalo Therapeutics to $40 From $29, Maintains Outperform Rating	MT
03-24	Wedbush Raises Price Target on Avalo Therapeutics to $29 From $28, Keeps Outperform Rating	MT
02-02	Guggenheim Initiates Coverage on Avalo Therapeutics With Buy Rating, $50 Price Target	MT
12-18	Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target	MT
05/09/25	TD Cowen Initiates Avalo Therapeutics at Buy	MT
15/08/25	Cantor Fitzgerald Initiates Avalo Therapeutics at Overweight	MT
25/03/25	Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target	MT
28/02/25	Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target	MT
21/02/25	Wedbush Initiates Avalo Therapeutics With Outperform Rating, $18 Price Target	MT
19/12/24	BTIG Research Initiates Avalo Therapeutics With Buy Rating, $40 Price Target	MT
24/10/24	HC Wainwright Initiates Avalo Therapeutics at Neutral	MT
16/04/24	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT
27/06/23	Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target	MT
27/06/23	Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept	MT
10/05/23	RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier	MT
08/02/23	Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50	MT
09/11/22	Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating	MT
08/08/22	Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating	MT
05/08/22	RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier	MT
11/07/22	RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept	MT
06/05/22	RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AVALO THERAPEUTICS, INC.					+125.39%
	WUXI APPTEC CO., LTD.					+16.85%
	ARGENX SE					+9.86%
	WUXI BIOLOGICS (CAYMAN) INC.					+10.81%
	INSMED INCORPORATED					+68.87%
	BIONTECH SE					+17.86%
	PHARMAESSENTIA CORPORATION					-13.15%
	GENMAB A/S					+12.58%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+20.2%
	EXELIXIS, INC.					-2.66%
	Average					+26.66%
	Weighted average by Cap.					+16.74%